Clinical Studies/Trials

Initial results of ReCor’s REDUCE First-In-Man clinical study presented at “TRenD 2012” transcatheter renal denervation scientific meeting as company gains CE mark for its PARADISE™ system.

Transdermal glucose monitoring future style, as well as potential for drug delivery from this new technology.

Is AF Ablation surgery a way of treating the symptoms of atrial fibrillation or the underlying natural history? Refreshing opinion piece from a US cardiologist.

Clinical results from a study on the use of flow diversion in peripheral neurological vessels suggest the therapeutic solution has a place.

Medtronic’s newly announced patient registry and heart failure studies will inform on the effectiveness of renal denervation.

Infusing Cardiac stem cells into post-infarct patients seems to reduce scarring and increase myocardium.

The Prometra implantable, programmable pump from Medasys, represents the first non-peristaltic drug-infusion device to gain PMA approval. The product is already CE marked and available in selected European countries, with full EU roll-out expected in the next few months.

Brazilian developers of the Inovare transapical aortic valve are encouraged by the early experience with the device despite a 50% two-year mortality rate.

Boston Scientific is sounding pretty pleased with itself as it publicises positive results from three major studies on its WallFlex® enteral stent family of products.

Zimmer Nexgen Knee Tibial component under the spotlight as Mayo clinic divulges high rate of loosening.

Patients who underwent coronary angioplasty with InspireMD’s MGuard coronary stent exhibited statistically significant improvement in microvascular reperfusion criteria compared with those treated with traditional bare metal stents (BMS).

Covidien’s stent-like clot retrieval device, SOLITAIRE FR, worked well enough in this randomised study to persuade the safety monitoring committee to end the trial early.

An expanded patient group in the PARTNER heart valve study suggests a trend towards enhanced survival, reduced symptoms and stroke risk.

UK surgical sealant film company Tissuemed Ltd. has announced the publication of a new clinical paper in World Neurosurgery relating to its self-adhesive dural sealant film products.

Covidien’s Solitaire FR device has been accepted into US stroke trial on an investigational basis. Company financials look strong and sounds bullish about the forthcoming tax levy.

Covidien’s Everflex system, designed to treat long vascular lesions with a single stent, is the subject of an extensive clinical study, interim results of which have been released. The stent is already approved for use in Europe.